Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Paroxetine
Drug ID BADD_D01679
Description Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others.[T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters.[A31914] Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class.[A31914] The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Indications and Usage Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder.[L3358] One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause.[L7703] Off-label, paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome (IBS).[A1093,A181754,A181904]
Marketing Status approved; investigational
ATC Code N06AB05
DrugBank ID DB00715
KEGG ID D02362
MeSH ID D017374
PubChem ID 43815
TTD Drug ID D06GDY
NDC Product Code 13107-157; 61919-512; 61919-658; 62135-544; 63629-3349; 70518-3518; 72241-029; 72241-031; 13107-156; 58118-0183; 62135-425; 63187-105; 69367-336; 72241-030; 55289-972; 68071-1740; 68180-646; 68180-647; 68382-099; 62135-426; 63187-564; 69367-335; 70518-0003; 70518-3277; 70518-3613; 72189-492; 50268-643; 60760-501; 62135-427; 62135-543; 68382-098; 68788-7410; 69117-0026; 70518-3430; 0574-0279; 71610-056; 62135-542; 63187-434; 68180-645; 68788-6870; 69117-0024; 70954-319; 71209-094; 71335-0321; 0615-8174; 61919-322; 61919-596; 69117-0025; 71209-096; 71335-0544; 43353-713; 43547-409; 63629-1840; 63739-963; 68382-097; 69117-0027; 70518-2465; 70518-2574; 71209-095; 0615-8173; 13107-155; 50268-640; 62135-541; 68382-001; 69367-337; 0615-8359; 80425-0339; 50268-642; 60760-398; 63187-190; 63739-888; 13107-154
UNII 41VRH5220H
Synonyms Paroxetine | Aropax | BRL-29060 | BRL 29060 | BRL29060 | FG-7051 | FG 7051 | FG7051 | Paroxetine Acetate | Seroxat | Paroxetine Hydrochloride Anhydrous | Paroxetine Maleate | Paroxetine, cis-(+)-Isomer | Paroxetine, cis-(-)-Isomer | Paroxetine, trans-(+)-Isomer | Paxil | Paroxetine Hydrochloride Hemihydrate | Paroxetine Hydrochloride, Hemihydrate | Paroxetine Hydrochloride
Chemical Information
Molecular Formula C19H20FNO3
CAS Registry Number 61869-08-7
SMILES C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Toxic epidermal necrolysis10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.008--
Tremor17.01.06.0020.000339%
Tricuspid valve incompetence02.07.05.0010.000322%-
Trigeminal neuralgia17.04.08.001---
Trismus15.05.04.004; 17.01.03.004--
Ulcer08.03.06.001---
Urethritis11.01.14.008; 20.07.02.001--
Urinary casts13.13.02.014---
Urinary hesitation20.02.02.009---
Urinary incontinence17.05.01.008; 20.02.02.0100.000064%
Urinary retention20.02.02.0110.000107%
Urinary tract infection11.01.14.004; 20.08.02.001--
Urine abnormality20.02.01.013---
Urticaria10.01.06.001; 23.04.02.001--
Uterine leiomyoma16.04.02.001; 21.07.02.004---
Uterine neoplasm16.12.06.002; 21.07.02.008---
Uterine spasm21.07.03.002---
Vaginal discharge21.08.02.002--
Vaginal haemorrhage21.08.01.001; 24.07.03.0050.000189%
Vaginal infection11.01.10.002; 21.14.02.002--
Varicose vein24.10.04.001---
Vascular headache17.14.01.005; 24.03.05.007---
Vascular purpura01.01.04.007; 23.06.01.008; 24.07.06.011---
Ventricular extrasystoles02.03.04.0070.000043%-
Ventricular fibrillation02.03.04.008--
Ventricular hypertrophy02.04.02.0120.000107%-
Ventricular tachycardia02.03.04.010--
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred06.02.06.007; 17.17.01.010--
Visual acuity reduced06.02.10.012; 17.17.01.0110.000043%
The 21th Page    First    Pre   21 22 23 24 25    Next   Last    Total 28 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene